Global Sterile Oncology Injectable Market Trends, Analysis, Growth, and Forecast: 2017 to 2026
MarketResearch.Biz delivers in-depth insights on the global sterile oncology injectable market in its upcoming report titled, “Global Sterile Oncology Injectable Market Trends, Analysis, Growth, and Forecast: 2017 to 2026”. The global sterile oncology injectable market is estimated to register a CAGR of X.X% in terms of value during forecast period 2017–2026. The report offers in-depth insights, revenue details, and other vital information regarding the global sterile oncology injectable market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026. The report offers insightful and detailed information regarding the various key players operating in the global sterile oncology injectable market, their financials, supply chain trends, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global sterile oncology injectable market report has been segmented on the basis of product type, disease indication, distribution channel, and region.
This report is based on synthesis, analysis, and interpretation of information gathered regarding the target market from various sources. Our analysts have analysed the information and data and gained insights using a mix of primary and secondary research efforts with the primary objective to provide a holistic view of the market. In addition, an in-house study has been made of the global economic conditions and other economic indicators and factors to assess their respective impact on the market historically, as well as the current impact in order to make informed forecasts about the scenarios in future.
Sterile injectable molecules are used as active substances which is divided into two class, large and small molecule as they differ in size, manufacturing process, mode of action in the body. Sterile injectable are used in treatment of various cancer such as breast, lung, and ovarian cancer.
Increasing investment in R&D by major players in target market for developing disease specific drugs is expected is a major factor contributing for the growth of the global sterile oncology injectable market. In addition, increasing incidence of cancer is another factor expected to drive the growth of the global sterile oncology injectable market. According to American Cancer Society, 1.6 Mn new cancer cases and 600,920 cancer deaths have been projected to occur in the US in 2017. It also stated that the cancer incidence rate is 20% higher in men than in women. Furthermore, increasing number for drug approvals by health authority for injectable and subsequent launching and commercialization of innovative drugs is anticipated to further drive the growth of global sterile oncology injectable market over the forecast period.
High cost of manufacturing is a major factor expected to hamper the growth of the global sterile oncology injectable market over the forecast period.
However, company focusing on developing innovative drugs that can absorb in body quickly providing quick therapeutic response, will create new opportunities for new as well as existing players in the global sterile oncology injectable market over the forecast period.
North America market dominates the global sterile oncology injectable market in terms of revenue contribution as compared to that of markets in the region. Europe accounts for second-largest revenue share contribution to the global sterile oncology injectable market, followed by markets in Latin America, Asia Pacific, and Middle East & Africa respectively. The market in Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years, owing to the increasing incidence of cancer and improving healthcare infrastructure in the region.
Global Sterile Oncology Injectable Market Segmentation:
Global sterile oncology injectable market segmentation, by product type:
- Monoclonal Antibodies
- Peptide Hormones
Global sterile oncology injectable market segmentation, by disease indication:
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
Global sterile oncology injectable market segmentation, by distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global sterile oncology injectable market segmentation, by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2020 Estimated Year 2021 Forecast Period 2021–2030 Revenue in US$
- Eli Lilly & Company
- Biocon Ltd.
- Baxter International Inc.
- Hikma Pharmaceuticals PLC
- Mylan N.V.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Novartis AG
- GlaxoSmithKline plc
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!